reports
Temenos AG: 1 director
A director at Temenos AG bought 315 shares at 55.451CHF and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Biomarin Pharmaceutical Inc: 2 directors
Two Directors at Biomarin Pharmaceutical Inc sold after exercising options/sold 6,850 shares at between 82.910USD and 85.010USD. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Selskabsmeddelelse nr. 02/2024 - Regnskabsmeddelelse, ...
Coloplast A/S - Selskabsmeddelelse nr. 02/2024 - Regnskabsmeddelelse, 1. halvår 2023/24 H1 2023/24Regnskabsmeddelelse, 1. halvår 2023/241. oktober 2023 – 31. marts 2024 Coloplast leverede et solidt 2. kvartal med 8% organisk vækst og en overskudsgrad1) på 27%. Den rapporterede omsætning målt i danske kroner steg 9% med 4 procentpoint bidrag fra Kerecis (underliggende vækst på ca. 35%), delvist udlignet af valutaer. Den organiske vækst pr. forretningsområde var 7% i Stomi, 8% i Kontinens, 13% i Stemme og Respiratorisk Pleje, 8% i Avanceret Sårpleje (8% i Avancerede Sårbandag...
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H...
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24 H1 2023/24Interim financial results, H1 2023/241 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%.Continu...
TFS Financial Corp: 1 director
A director at TFS Financial Corp sold 13,400 shares at 13.140USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
HCA Healthcare Inc: 1 director
A director at HCA Healthcare Inc sold 1,863 shares at 312.000USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
PWR Holdings Limited: 1 director
A director at PWR Holdings Limited maiden bought 10,000 shares at 11.950AUD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
- ABGSC Healthcare Research
- Morten Larsen
ARKEMA : RÉSULTATS DU 1ER TRIMESTRE 2024
COLOMBES, France--(BUSINESS WIRE)-- Regulatory News: Arkema (Paris:AKE): Chiffre d’affaires de 2,3 Mds€, en baisse de 7,3 % par rapport à l’an dernier : Légère progression des volumes sur les 3 segments de Matériaux de Spécialités (+ 2,7 %) Bonne dynamique sur certains marchés comme le collage structural, le sport, l’automobile et l’énergie Effet prix de - 8,4 % aux bornes des Matériaux de Spécialités, reflétant essentiellement la baisse des matières premières et les conditions de marché encore défavorables dans l’amont acrylique et le PVDF EBITDA de 350 M€, en léger retrait...
Eezy Plc's Interim Report 1–3/2024: Demand for staffing services remai...
Eezy Plc's Interim Report 1–3/2024: Demand for staffing services remains weak – focus on increasing productivity EEZY PLC -- INTERIM REPORT -- 7 MAY 2024 AT 8:00 Eezy Plc's Interim Report 1–3/2024: Demand for staffing services remains weak – focus on increasing productivity January–March 2024 Revenue was EUR 41.5 million (EUR 52.8 million in January–March 2023). Revenue decreased by 21%.EBITDA was EUR 2.3 million (3.4).EBIT was EUR 0.5 million (1.3) and was 1.2% of revenue (2.5%).EUR 0.3 million in personnel expenses related to severance payments were recorded in the result.Earnings ...
Aspo-konsernin osavuosikatsaus 1.1.–31.3.2024: Vahvaa strategian toteu...
Aspo-konsernin osavuosikatsaus 1.1.–31.3.2024: Vahvaa strategian toteutusta haastavassa toimintaympäristössä Aspo Oyj Osavuosikatsaus 7.5.2024 klo 8.00Aspo-konsernin osavuosikatsaus 1.1.–31.3.2024 Vahvaa strategian toteutusta haastavassa toimintaympäristössä Suluissa on esitetty vuoden 2023 vastaavan ajanjakson luvut. Tammi–maaliskuu 2024 Liikevaihto jatkuvista toiminnoista laski ja oli 132,7 Me (141,6).Vertailukelpoinen jatkuvien toimintojen liikevoitto oli 4,8 Me (8,4) eli 3,6 % (5,9) liikevaihdosta. ESL Shippingin vertailukelpoinen liikevoitto oli 2,7 Me (6,0), Telkon 2,2 Me (2,7) j...
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Busine...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2024. Participants during the call will be: Hervé Brailly, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financ...
Eezy Oyj:n osavuosikatsaus 1–3/2024: Henkilöstöpalveluiden kysyntä ede...
Eezy Oyj:n osavuosikatsaus 1–3/2024: Henkilöstöpalveluiden kysyntä edelleen vaimeaa – katse tuottavuuden nostamisessa EEZY OYJ -- OSAVUOSIKATSAUS -- 7.5.2024 KLO 8.00 Eezy Oyj:n osavuosikatsaus 1–3/2024: Henkilöstöpalveluiden kysyntä edelleen vaimeaa – katse tuottavuuden nostamisessa Tammi–maaliskuu 2024 Liikevaihto oli 41,5 milj. euroa (52,8 milj. euroa tammi–maaliskuussa 2023). Liikevaihto laski 21 %.Käyttökate oli 2,3 milj. euroa (3,4).Liikevoitto oli 0,5 milj. euroa (1,3) ja oli 1,2 % liikevaihdosta (2,5 %).Tulokseen sisältyy työsuhteiden päättymisiin liittyviä henkilöstökuluja 0,3...
Valneva Reports First Quarter 2024 Financial Results and Provides Cor...
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidance Cash position of €176.6 million, including €95 million from sale of Priority Review Voucher (PRV)1. Significantly extended cash runway with recent update of debt financing agreement2Substantially lower cash burn expected in 2024 as Valneva expects to complete...
Solvay first quarter 2024 results
Solvay first quarter 2024 results Strong FCF supported by resilient EBITDA and discipline on costs and capex Brussels, May 7, 2024 – 7:00 am CEST - regulated information Highlights Net sales for Q1 2024 at €1,201 million were down -11.9% organically versus Q1 2023, with positive volume impact, for the first time in seven quarters, in both Basic and Performance Chemicals segments. Prices decreased, mostly reflecting the lower energy and raw material costs.Underlying EBITDA of €265 million for the first quarter was -13.6% lower organically compared to a high Q1 2023, with negative Net ...
Valneva publie ses résultats financiers du premier trimestre 2024 et f...
Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités Principaux éléments financiers du premier trimestre Chiffre d’affaires total de 32,8 millions d’euros dont 32,1 millions d’euros de ventes de produits, en ligne avec les prévisions pour l'exercice 2024Position de trésorerie de 176,6 millions d’euros dont 95 millions d’euros provenant de la vente du bon de revue prioritaire (PRV)1. Extension significative de la visibilité financière ...
Résultats du premier trimestre 2024
Résultats du premier trimestre 2024 Information réglementée Un FCF solide soutenu par un EBITDA résilient et la gestion maîtrisée des coûts et des investissements Bruxelles, le 7 mai 2024 à 7h00 CEST - information réglementée Faits marquants Le chiffre d'affaires net du T1 2024 s’élève à €1 201 millions, en baisse organique de -11,9% par rapport au T1 2023, avec un impact positif des volumes pour la première fois en sept trimestres, visible à la fois dans les segments Basic Chemicals et Performance Chemicals. Les prix diminuent, reflétant principalement la baisse des coûts de l'énergie...
Resultaten Solvay van het eerste kwartaal 2024
Resultaten Solvay van het eerste kwartaal 2024 Gereglementeerde informatie Sterke vrije kasstroom ondersteund door veerkrachtige EBITDA en beheersing van kosten en investeringen Brussel, 7 mei 2024, om 7u00 CEST - gereglementeerde informatie Hoogtepunten De netto-omzet voor Kw1 2024 van €1 201 miljoen daalde op organische basis met -11,9% ten opzichte van Kw1 2023, met een positieve volume-impact, voor het eerst in zeven kwartalen, in zowel de segmenten Basic Chemicals als Performance Chemicals. De prijzen daalden, vooral door lagere energie- en grondstofkosten.De onderliggende EBITDA...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.